Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(4792)
•••

Comment by nozzpackon Dec 02, 2021 6:46pm

201 Views

Post# 34192587

RE:RE:RE:4 Quarter Trends in Absorica and Absorica +

Jeez, this is turning out to be a Mike Hammer dialogue.
Go ahead .
Make my day.
Im starting to enjoy it.

Cash is heavily discounted setting fallow in the treasury .

Gross margins are very rich, and I don't see much evidence that revenues will decline.
Then, there is Moby .
Its value will grow as its emancipation gets closer.

So, sitting pretty and waiting isn't all that bad of a deal..

<< Previous

Bullboard Posts

Next >>

A Critical Metal On Every Government's Radar as China Trade Tensions Rise